JPH10114655A - Slid pharmaceutical preparation - Google Patents
Slid pharmaceutical preparationInfo
- Publication number
- JPH10114655A JPH10114655A JP26876196A JP26876196A JPH10114655A JP H10114655 A JPH10114655 A JP H10114655A JP 26876196 A JP26876196 A JP 26876196A JP 26876196 A JP26876196 A JP 26876196A JP H10114655 A JPH10114655 A JP H10114655A
- Authority
- JP
- Japan
- Prior art keywords
- solid preparation
- preparation according
- amount
- salt
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は固形製剤に関する。TECHNICAL FIELD The present invention relates to a solid preparation.
【０００２】[0002]
【従来の技術】ピペリジノアルカノール誘導体は、日局
Ｉ液（ｐＨ１．２）でわずかに溶解する。そのため、ピ
ペリジノアルカノール誘導体からなる製剤は、日局Ｉ液
で製剤表面に溶解したピペリジノアルカノール誘導体の
薄いゲル状の膜が生成する。この膜は水分の透過を阻害
し、ピペリジノアルカノール誘導体からなる製剤の崩壊
時間が遅延するため、生体内の吸収が不十分となり生体
利用率が低くなる。この欠点を解消するため、特開平１
−１２８９２４公報では、非イオン性表面活性剤あるい
は陽イオン性表面活性剤、および炭酸カルシウムを含ん
でなる製剤組成物が開示されている。しかし、この方法
では安全性の面から必ずしも好ましくない表面活性剤を
使う必要がある。2. Description of the Related Art Piperidinoalkanol derivatives are slightly soluble in Japanese Pharmacopoeia solution I (pH 1.2). Therefore, in the preparation comprising the piperidinoalkanol derivative, a thin gel-like film of the piperidinoalkanol derivative dissolved on the surface of the preparation with the Japanese Pharmacopoeia I solution is formed. This membrane inhibits the permeation of water and delays the disintegration time of the preparation comprising the piperidinoalkanol derivative, resulting in insufficient absorption in the living body and low bioavailability. To solve this drawback, Japanese Patent Application Laid-Open
JP-A-128924 discloses a pharmaceutical composition comprising a nonionic surfactant or a cationic surfactant, and calcium carbonate. However, in this method, it is necessary to use a surfactant which is not necessarily preferable in terms of safety.
【０００３】[0003]
【発明が解決しようとする課題】本発明は、表面活性剤
を使用することなく、日局Ｉ液で迅速に崩壊する製剤を
提供することにある。An object of the present invention is to provide a preparation which disintegrates rapidly with Japanese Pharmacopoeia solution I without using a surfactant.
【０００４】[0004]
【課題を解決するための手段】本発明は、治療上有効量
の少なくとも一種の薬剤、少なくとも一種の中性あるい
は塩基性の添加物、および崩壊剤を含有してなる固形製
剤に関する。SUMMARY OF THE INVENTION The present invention relates to a solid preparation comprising a therapeutically effective amount of at least one drug, at least one neutral or basic additive, and a disintegrant.
【０００５】[0005]
【発明の実施の形態】本発明における薬剤としては、酸
性ｐＨ溶液中でゲル状膜を生成する薬剤があげられる。
該薬剤としてはピペリジノアルカノール誘導体もしくは
製薬上許容されるその塩が例示され、具体的にはテルフ
ェナジンがあげられる。固形製剤としては、錠剤、カプ
セル剤、顆粒剤、散剤などが例示される。一製剤あたり
の含有量は６０〜１２０ｍｇが好ましい。BEST MODE FOR CARRYING OUT THE INVENTION The drug in the present invention includes a drug which forms a gel-like film in an acidic pH solution.
Examples of the drug include a piperidinoalkanol derivative or a pharmaceutically acceptable salt thereof, and specific examples include terfenadine. Examples of the solid preparation include tablets, capsules, granules, powders and the like. The content per preparation is preferably from 60 to 120 mg.
【０００６】添加物としては、無機物および有機物があ
り、無機物としては無水ケイ酸、特殊ケイ酸カルシウ
ム、メタケイ酸アルミン酸マグネシウムなどのケイ酸類
もしくはその塩、リン酸水素カルシウム、リン酸カルシ
ウムなどのリン酸塩、水酸化アルミニウムなどの金属酸
化物などがあげられ、好ましくは、メタケイ酸アルミン
酸マグネシウムや特殊ケイ酸カルシウムである。有機物
としては、有機酸の塩、多糖類、アミノ酸類、蛋白質類
などがあげられる。有機酸の塩としては、酢酸ナトリウ
ムやクエン酸ナトリウムなどがあげられ、多糖類として
はカルボキシメチルセルロースナトリウムや結晶セルロ
ースなどがあげられ、アミノ酸類としてはアラニン、ロ
イシン、リジン、アルギニンなどがあげられ、蛋白質類
としてはゼラチンなどがあげられるが、好ましくはラク
トースや結晶セルロース等の糖類である。The additives include inorganic substances and organic substances. Examples of the inorganic substances include silicic acids such as silicic anhydride, special calcium silicate, and magnesium aluminate metasilicate or salts thereof, and phosphates such as calcium hydrogen phosphate and calcium phosphate. And metal oxides such as aluminum hydroxide. Preferred are magnesium metasilicate aluminate and special calcium silicate. Organic substances include salts of organic acids, polysaccharides, amino acids, proteins and the like. Salts of organic acids include sodium acetate and sodium citrate, etc., polysaccharides include sodium carboxymethylcellulose and crystalline cellulose, and amino acids include alanine, leucine, lysine, arginine, etc. Examples of the class include gelatin and the like, and preferred are saccharides such as lactose and crystalline cellulose.
【０００７】崩壊剤としては、クロスポビドン、低置換
度ヒドロキシプロピルセルロース、クロスカルメロース
ナトリウム、カルボキシメチルセルロース、カルボキシ
メチルセルロースカルシウム、カルボキシメチルスター
チナトリウム、部分アルファ化デンプンなどがあげられ
るが、好ましくは、クロスポビドン、低置換度ヒドロキ
シプロピルセルロース、クロスカルメロースナトリウム
である。Examples of the disintegrant include crospovidone, low-substituted hydroxypropylcellulose, croscarmellose sodium, carboxymethylcellulose, carboxymethylcellulose calcium, carboxymethyl starch sodium, partially pregelatinized starch, etc., and preferably crospovidone. Low-substituted hydroxypropylcellulose and croscarmellose sodium.
【０００８】製剤中の添加物および崩壊剤の含有量は、
それぞれ０．１〜３０重量％および１〜３０重量％であ
り、好ましくはそれぞれ５〜２０重量％および１〜５重
量％である。本発明の固形製剤は、薬剤、添加物および
崩壊剤、場合によっては滑沢剤などを混合することによ
りなる。さらに、一般的に用いられる甘味剤、着色剤、
香味剤、抗酸化剤などを添加し、製剤化することも可能
である。固形製剤の製造法としては、例えば、薬剤、添
加物および崩壊剤の混合粉体を直接打錠あるいはカプセ
ル充填する方法、または一旦乾式や湿式で造粒し、乾
燥、整粒する方法などがあげられるが、一般に製剤を製
造する方法であれば特に制限はなく、いずれの方法でも
よい。錠剤またはカプセル剤を製造する際には、少量の
滑沢剤を混合することもできる。錠剤またはカプセル剤
を製造する際に用いられる滑沢剤としては、ステアリン
酸マグネシウム、ステアリン酸カルシウム、ステアリン
酸亜鉛、ステアリン酸、滑石、水素添加植物油、タルク
などがあげられるが、好ましくはステアリン酸マグネシ
ウム、ステアリン酸カルシウムである。滑沢剤の添加方
法としては、一般的な内部滑沢法、あるいは外部滑沢機
を用いた外部滑沢法などがあげられる。さらに、錠剤に
各種の皮膜あるいは糖衣などでコーティングすることも
可能である。[0008] The content of additives and disintegrants in the formulation is
They are respectively 0.1 to 30% by weight and 1 to 30% by weight, preferably 5 to 20% by weight and 1 to 5% by weight, respectively. The solid preparation of the present invention is obtained by mixing a drug, an additive, a disintegrant, and in some cases, a lubricant. In addition, commonly used sweeteners, coloring agents,
It is also possible to add a flavoring agent, an antioxidant and the like to form a preparation. Examples of the method for producing a solid preparation include a method in which a mixed powder of a drug, an additive, and a disintegrant is directly tableted or filled with capsules, or a method in which granulation is performed once in a dry or wet method, followed by drying and sizing. However, there is no particular limitation as long as it is a method for producing a preparation, and any method may be used. In preparing tablets or capsules, small amounts of lubricants may be mixed. Lubricants used in the manufacture of tablets or capsules include magnesium stearate, calcium stearate, zinc stearate, stearic acid, talc, hydrogenated vegetable oils, talc and the like, preferably magnesium stearate, It is calcium stearate. Examples of the method of adding the lubricant include a general internal lubrication method and an external lubrication method using an external lubricator. Further, the tablets can be coated with various kinds of films or sugar coating.
【０００９】以下の実施例によって本発明を具体的に説
明する。The present invention will be specifically described by the following examples.
【００１０】[0010]
【００１１】実施例１ テルフェナジン、乳糖（ＤＭＶ社製：２００Ｍ）、トウ
モロコシ殿粉（日本食品化工社製：日食コーンスターチ
W ）、メタケイ酸アルミン酸マグネシウム（富士化学社
製：ノイシリンＵＦＬ２）、クロスポピドン（ＧＡＦ社
製：ポリプラスドンＸＬ−１０）、ヒドロキシプロピル
メチルセルロース（信越化学社製：ＴＣ−５Ｒ）を撹拌
造粒機（パウレック社製）内に仕込み、精製水を添加し
造粒後、乾燥工程を経て造粒物を得た。造粒物にステア
リン酸マグネシウム（純正化学社製）を加えて混合後、
ロータリー型打錠機（菊水製作所製）を用い圧縮成形し
た。成形条件は錠剤重量２５０ｍｇ（テルフェナジン含
量６０ｍｇ）、金型は９ｍｍφ糖衣Ｒ型とし、錠剤硬度
が１３kgf の錠剤を得た。Example 1 Terfenadine, lactose (manufactured by DMV: 200M), maize starch (manufactured by Nippon Shokuhin Kako: eclipse corn starch)
W), magnesium aluminometasilicate (Fuji Chemical Co., Ltd .: Neusilin UFL2), crospovidone (GAF Co .: Polyplasdone XL-10), and hydroxypropyl methylcellulose (Shin-Etsu Chemical Co., Ltd .: TC-5R) The mixture was charged into a machine (manufactured by Powrex), purified water was added thereto, and the mixture was granulated, followed by a drying step to obtain a granulated product. After adding and mixing magnesium stearate (manufactured by Junsei Chemical Co., Ltd.)
It was compression molded using a rotary tableting machine (manufactured by Kikusui Seisakusho). The molding conditions were a tablet weight of 250 mg (terfenadine content 60 mg), a die of 9 mmφ sugar-coated R type, and a tablet having a tablet hardness of 13 kgf.
【００１２】実施例２ 実施例１のメタケイ酸アルミン酸マグネシウムの量を５
重量％にし、実施例１と同様の方法により２５０ｍｇの
錠剤を得た。Example 2 The amount of magnesium aluminate metasilicate of Example 1 was 5
In the same manner as in Example 1, 250 mg tablets were obtained.
【００１３】実施例３ 実施例１のメタケイ酸アルミン酸マグネシウムの量を２
０重量％にし、実施例１と同様の方法により２５０ｍｇ
の錠剤を得た。実施例１から３についての処方を第１表
に示す。Example 3 The amount of magnesium aluminate metasilicate of Example 1 was changed to 2
0% by weight and 250 mg by the same method as in Example 1.
Tablets were obtained. Table 1 shows the formulations for Examples 1 to 3.
【００１４】[0014]
【表１】 [Table 1]
【００１５】実施例４ 実施例１のテルフェナジンの量を４８重量％にし、実施
例１と同様の方法により２５０ｍｇの錠剤を得た（テル
フェナジン含量１２０ｍｇ）。実施例４についての処方
を第２表に示す。Example 4 A 250 mg tablet (terfenadine content: 120 mg) was obtained in the same manner as in Example 1 except that the amount of terfenadine in Example 1 was changed to 48% by weight. The formulation for Example 4 is shown in Table 2.
【００１６】[0016]
【表２】 [Table 2]
【００１７】実施例５ 実施例１のメタケイ酸アルミン酸マグネシウムを特殊ケ
イ酸カルシウム（エーザイ社製：フローライトＲＥ）に
変え、実施例１と同様の方法により２５０ｍｇの錠剤を
得た。実施例５についての処方を第３表に示す。Example 5 A 250 mg tablet was obtained in the same manner as in Example 1, except that the magnesium aluminate metasilicate of Example 1 was changed to a special calcium silicate (Florite RE, manufactured by Eisai Co.). The formulation for Example 5 is shown in Table 3.
【００１８】[0018]
【表３】 [Table 3]
【００１９】実施例６ 実施例１のクロスポピドンの量を１重量％にし、実施例
１と同様の製造法により２５０ｍｇの錠剤を得た。Example 6 A 250 mg tablet was obtained in the same manner as in Example 1 except that the amount of crospovidone in Example 1 was changed to 1% by weight.
【００２０】実施例７ 実施例１のクロスポピドンの量を３重量％にし、実施例
１と同様の製造法により２５０ｍｇの錠剤を得た。実施
例６および実施例７についての処方を第４表に示す。Example 7 A 250 mg tablet was obtained by the same production method as in Example 1 except that the amount of crospovidone in Example 1 was changed to 3% by weight. The formulations for Examples 6 and 7 are shown in Table 4.
【００２１】[0021]
【表４】 [Table 4]
【００２２】実施例８ 実施例１のクロスポピドンをカルボキシメチルセルロー
ス（五徳薬品社製：ＮＳ−３００）に変え、実施例１と
同様の方法により２５０ｍｇの錠剤を得た。Example 8 The procedure of Example 1 was repeated, except that crospovidone in Example 1 was changed to carboxymethylcellulose (NS-300, manufactured by Gotoku Yakuhin Co., Ltd.).
【００２３】実施例９ 実施例８のカルボキシメチルセルロースの量を３重量％
にし、実施例１と同様の製造法により２５０ｍｇの錠剤
を得た。実施例８および実施例９についての処方を第５
表に示す。Example 9 The amount of carboxymethylcellulose of Example 8 was 3% by weight.
In the same manner as in Example 1, 250 mg of tablets were obtained. The formulation for Examples 8 and 9 was
It is shown in the table.
【００２４】[0024]
【表５】 [Table 5]
【００２５】実施例１０ 実施例１のクロスポピドンを低置換度ヒドロキシプロピ
ルセルロース（信越化学社製：Ｌ−ＨＰＣ ＬＨ−１
１）に変え、実施例１と同様の方法により２５０ｍｇの
錠剤を得た。Example 10 The crospopidone of Example 1 was replaced with low-substituted hydroxypropylcellulose (L-HPC LH-1 manufactured by Shin-Etsu Chemical Co., Ltd.).
1) was changed to 1), and a tablet of 250 mg was obtained in the same manner as in Example 1.
【００２６】実施例１１ 実施例８の低置換度ヒドロキシプロピルセルロースの量
を３重量％にし、実施例１と同様の製造法により２５０
ｍｇの錠剤を得た。実施例１０および実施例１１につい
ての処方を第６表に示す。Example 11 The amount of the low-substituted hydroxypropylcellulose in Example 8 was changed to 3% by weight, and 250% was obtained by the same production method as in Example 1.
mg tablets were obtained. The formulations for Examples 10 and 11 are shown in Table 6.
【００２７】[0027]
【表６】 [Table 6]
【００２８】実施例１２ 実施例１と同様にして得られた造粒物２５０ｍｇを白色
１号ゼラチン硬カプセル（エランコ社製）に充填し、カ
プセル剤を得た。実施例１２についての処方を第７表に
示す。Example 12 250 mg of a granulated product obtained in the same manner as in Example 1 was filled in a white No. 1 gelatin hard capsule (manufactured by Elanco) to obtain a capsule. The formulation for Example 12 is shown in Table 7.
【００２９】[0029]
【表７】 [Table 7]
【００３０】比較例１ 実施例１のメタケイ酸アルミン酸マグネシウムを乳糖に
置き換え、実施例１と同様の製造法により錠剤を得た。
比較例１についての処方を第８表に示す。Comparative Example 1 Tablets were obtained in the same manner as in Example 1 except that the magnesium aluminate metasilicate of Example 1 was replaced with lactose.
Table 8 shows the formulation for Comparative Example 1.
【００３１】[0031]
【表８】 [Table 8]
【００３２】比較例２ 実施例１のクロスポピドンを乳糖に置き換え、実施例１
と同様の製造法により錠剤を得た。比較例２についての
処方を第９表に示す。Comparative Example 2 Example 1 was repeated except that crospovidone in Example 1 was replaced with lactose.
Tablets were obtained in the same manner as in the above. Table 9 shows the formulation for Comparative Example 2.
【００３３】[0033]
【表９】 [Table 9]
【００３４】比較例３ 比較例１と同様にして得られた造粒物を実施例１２と同
様の製造法によりカプセル剤を得た。比較例３について
の処方を第１０表に示す。Comparative Example 3 A granule obtained in the same manner as in Comparative Example 1 was obtained in the same manner as in Example 12 to obtain a capsule. The formulation for Comparative Example 3 is shown in Table 10.
【００３５】[0035]
【表１０】 [Table 10]
【００３６】試験例 実施例１〜１２および比較例１〜３で得られた錠剤を日
局１２に準じ崩壊試験を行った。試験液は日局準拠Ｉ液
（pH１．２）および蒸留水を用いた。日局準拠Ｉ液（pH
１．２）および蒸留水を用いたときの崩壊時間を、以下
の表に示す。Test Example The tablets obtained in Examples 1 to 12 and Comparative Examples 1 to 3 were subjected to a disintegration test in accordance with JP12. The test solution used was Japanese Pharmacopoeia-compliant solution I (pH 1.2) and distilled water. JP-compliant I solution (pH
1.2) and the disintegration time when using distilled water are shown in the following table.
【００３７】[0037]
【表１１】 [Table 11]
【００３８】中性あるいは塩基性の添加物を添加した各
実施例の崩壊時間は、日局Ｉ液および蒸留水で差がなか
った。これに対し、中性あるいは塩基性の添加物を添加
しなかった、例えば比較例１は、日局Ｉ液では１時間を
経過しても全く崩壊せず、錠剤が膨潤した状態で残って
いた。これは、日局Ｉ液により主薬のテルフェナジンが
ゲル化し、錠剤の崩壊を阻害したためで、ゲル化しない
蒸留水では７分台と速い崩壊であった。The disintegration time of each of the examples to which a neutral or basic additive was added was not different between the Japanese Pharmacopoeia I solution and distilled water. On the other hand, the neutral or basic additive was not added, for example, in Comparative Example 1, the Japanese Pharmacopoeia I solution did not disintegrate at all after 1 hour, and the tablet remained in a swollen state. . This was because terfenadine as the main drug gelled by the Japanese Pharmacopoeia I solution and inhibited the disintegration of tablets, and the disintegration of non-gelled distilled water was as quick as 7 minutes.
【００３９】以上の結果より、メタケイ酸アルミン酸マ
グネシウムまたは特殊ケイ酸カルシウムの添加はＩ液で
は局部的にpHを中性にし、テルフェナジンのゲル化を防
いでいた。これにより、試験液に左右されることなく製
剤内に液を浸透させると考えられる。さらに、崩壊剤の
種類および添加量を変化させることにより、任意の崩壊
時間にすることも可能となった。From the above results, it was found that the addition of magnesium aluminate metasilicate or special calcium silicate locally neutralized the pH in Solution I and prevented gelation of terfenadine. Thereby, it is considered that the liquid permeates into the preparation without depending on the test liquid. Further, by changing the type and amount of the disintegrant, it is possible to set an arbitrary disintegration time.
【００４０】[0040]
【発明の効果】本発明によれば、表面活性剤を使用する
ことなく、日局Ｉ液で迅速に崩壊する固形製剤を提供す
ることができる。According to the present invention, it is possible to provide a solid preparation which rapidly disintegrates with JP I solution without using a surfactant.
Claims (10)
少なくとも一種の中性あるいは塩基性の添加物、および
崩壊剤を含有してなる固形製剤。1. A therapeutically effective amount of at least one agent,
A solid preparation comprising at least one neutral or basic additive and a disintegrant.
する薬剤である請求項１記載の固形製剤。2. The solid preparation according to claim 1, wherein the drug is a drug that forms a gel-like film in an acidic pH solution.
しくは製薬上許容されるその塩である請求項２記載の固
形製剤。3. The solid preparation according to claim 2, wherein the drug is a piperidinoalkanol derivative or a pharmaceutically acceptable salt thereof.
ェナジンである請求項３記載の固形製剤。4. The solid preparation according to claim 3, wherein the piperidinoalkanol derivative is terfenadine.
り、６０〜１２０ｍｇである請求項４記載の固形製剤。5. The solid preparation according to claim 4, wherein the content of terfenadine is 60 to 120 mg per preparation.
有機酸の塩、多糖類、アミノ酸類または蛋白質類である
請求項１記載の固形製剤。6. The neutral or basic additive is an inorganic substance,
The solid preparation according to claim 1, which is a salt of an organic acid, a polysaccharide, an amino acid or a protein.
ン酸塩または金属水酸化物である請求項６記載の固形製
剤。7. The solid preparation according to claim 6, wherein the inorganic substance is a silicic acid or a salt thereof, a phosphate or a metal hydroxide.
マグネシウムまたは特殊ケイ酸カルシウムである請求項
７記載の固形製剤。8. The solid preparation according to claim 7, wherein the salt of silicic acid is magnesium aluminate metasilicate or special calcium silicate.
ロキシプロピルセルロース、クロスカルメロースナトリ
ウム、カルボキシメチルセルロース、カルボキシメチル
セルロースカルシウム、カルボキシメチルスターチナト
リウムまたは部分アルファ化デンプンである請求項１記
載の固形製剤。9. The solid preparation according to claim 1, wherein the disintegrant is crospovidone, low-substituted hydroxypropylcellulose, croscarmellose sodium, carboxymethylcellulose, calcium carboxymethylcellulose, sodium carboxymethyl starch or partially pregelatinized starch.
０重量％および崩壊剤の含有量が１〜３０重量％である
請求項１記載の固形製剤。10. The content of the additive in the preparation is 0.1 to 3
The solid preparation according to claim 1, wherein the content of the disintegrant is 0% by weight and 1 to 30% by weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP26876196A JPH10114655A (en) | 1996-10-09 | 1996-10-09 | Slid pharmaceutical preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP26876196A JPH10114655A (en) | 1996-10-09 | 1996-10-09 | Slid pharmaceutical preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH10114655A true JPH10114655A (en) | 1998-05-06 |
Family
ID=17462962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP26876196A Withdrawn JPH10114655A (en) | 1996-10-09 | 1996-10-09 | Slid pharmaceutical preparation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH10114655A (en) |
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999009957A1 (en) * | 1997-08-26 | 1999-03-04 | Hoechst Marion Roussel, Inc. | Pharmaceutical composition for combination of piperidinoalkanol-decongestant |
| WO2000054752A1 (en) * | 1999-03-15 | 2000-09-21 | Kaken Pharmaceutical Co., Ltd. | Quickly disintegrating tablets and process for producing the same |
| LT4896B (en) | 2000-04-12 | 2002-02-25 | Bristol-Myers Squibb Company | Flash-melt oral dosage formulation |
| WO2003030868A1 (en) | 2001-10-09 | 2003-04-17 | Bristol-Myers Squibb Company | Flashmelt oral dosage formulation |
| US6610266B2 (en) | 2001-11-28 | 2003-08-26 | Michael C. Withiam | Calcium metasilicates and methods for making |
| WO2004052342A1 (en) * | 2002-12-09 | 2004-06-24 | Astrazeneca Ab | A new oral immediated release dosage form |
| JP2006131575A (en) * | 2004-11-08 | 2006-05-25 | Tokuyama Corp | Low-melting drug-containing granule and tablet produced by using the same |
| WO2007097333A1 (en) * | 2006-02-20 | 2007-08-30 | Asahi Breweries, Ltd. | Granules, tablets and method of producing the same |
| US7510728B2 (en) | 2000-10-06 | 2009-03-31 | Takeda Pharmaceutical Company Limited | Solid preparations |
| JP2014129238A (en) * | 2012-12-28 | 2014-07-10 | Lion Corp | Solid preparation including etodolac |
| US8962650B2 (en) | 2011-04-18 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
| US9334239B2 (en) | 2012-12-21 | 2016-05-10 | Eisai R&D Management Co., Ltd. | Amorphous form of quinoline derivative, and method for producing same |
| US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| US10259791B2 (en) | 2014-08-28 | 2019-04-16 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
| US10517861B2 (en) | 2013-05-14 | 2019-12-31 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| US11090386B2 (en) | 2015-02-25 | 2021-08-17 | Eisai R&D Management Co., Ltd. | Method for suppressing bitterness of quinoline derivative |
| US11369623B2 (en) | 2015-06-16 | 2022-06-28 | Prism Pharma Co., Ltd. | Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor |
| US11547705B2 (en) | 2015-03-04 | 2023-01-10 | Merck Sharp & Dohme Llc | Combination of a PD-1 antagonist and a VEGF-R/FGFR/RET tyrosine kinase inhibitor for treating cancer |
-
1996
- 1996-10-09 JP JP26876196A patent/JPH10114655A/en not_active Withdrawn
Cited By (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999009957A1 (en) * | 1997-08-26 | 1999-03-04 | Hoechst Marion Roussel, Inc. | Pharmaceutical composition for combination of piperidinoalkanol-decongestant |
| WO2000054752A1 (en) * | 1999-03-15 | 2000-09-21 | Kaken Pharmaceutical Co., Ltd. | Quickly disintegrating tablets and process for producing the same |
| LT4896B (en) | 2000-04-12 | 2002-02-25 | Bristol-Myers Squibb Company | Flash-melt oral dosage formulation |
| BG65007B1 (en) * | 2000-04-12 | 2006-12-29 | Bristol-Myers Squibb Company | Fast melting oral dosage form |
| US8518421B2 (en) | 2000-04-12 | 2013-08-27 | Bristol-Myers Squibb Company | Flashmelt oral dosage formulation |
| US7510728B2 (en) | 2000-10-06 | 2009-03-31 | Takeda Pharmaceutical Company Limited | Solid preparations |
| WO2003030868A1 (en) | 2001-10-09 | 2003-04-17 | Bristol-Myers Squibb Company | Flashmelt oral dosage formulation |
| US6610266B2 (en) | 2001-11-28 | 2003-08-26 | Michael C. Withiam | Calcium metasilicates and methods for making |
| WO2004052342A1 (en) * | 2002-12-09 | 2004-06-24 | Astrazeneca Ab | A new oral immediated release dosage form |
| JP2006131575A (en) * | 2004-11-08 | 2006-05-25 | Tokuyama Corp | Low-melting drug-containing granule and tablet produced by using the same |
| WO2007097333A1 (en) * | 2006-02-20 | 2007-08-30 | Asahi Breweries, Ltd. | Granules, tablets and method of producing the same |
| US8962650B2 (en) | 2011-04-18 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
| US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| US11598776B2 (en) | 2011-06-03 | 2023-03-07 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| US9334239B2 (en) | 2012-12-21 | 2016-05-10 | Eisai R&D Management Co., Ltd. | Amorphous form of quinoline derivative, and method for producing same |
| JP2014129238A (en) * | 2012-12-28 | 2014-07-10 | Lion Corp | Solid preparation including etodolac |
| US10517861B2 (en) | 2013-05-14 | 2019-12-31 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| US10259791B2 (en) | 2014-08-28 | 2019-04-16 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
| US10407393B2 (en) | 2014-08-28 | 2019-09-10 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
| US10822307B2 (en) | 2014-08-28 | 2020-11-03 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
| US11186547B2 (en) | 2014-08-28 | 2021-11-30 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
| US11090386B2 (en) | 2015-02-25 | 2021-08-17 | Eisai R&D Management Co., Ltd. | Method for suppressing bitterness of quinoline derivative |
| US11547705B2 (en) | 2015-03-04 | 2023-01-10 | Merck Sharp & Dohme Llc | Combination of a PD-1 antagonist and a VEGF-R/FGFR/RET tyrosine kinase inhibitor for treating cancer |
| US11369623B2 (en) | 2015-06-16 | 2022-06-28 | Prism Pharma Co., Ltd. | Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH10114655A (en) | Slid pharmaceutical preparation | |
| CA2311734C (en) | Flash-melt oral dosage formulation | |
| AU2001268719B2 (en) | Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates | |
| EP0879049B1 (en) | Process to prepare soluble delivery systems using volatile salts | |
| CA2440361A1 (en) | Intraorally rapidly disintegrable preparation | |
| AU2001268719A1 (en) | Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates | |
| KR20060097071A (en) | Immediate release tablet | |
| KR20010024184A (en) | Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient | |
| US20030118647A1 (en) | Extended release tablet of metformin | |
| CA2256751C (en) | Coated trimebutine maleate tablet | |
| JP2001278812A (en) | Disintegrant for tablet and tablet using the same | |
| JPS63165320A (en) | Solid composition and manufacture | |
| HU227759B1 (en) | Improved pharmaceutical formulations containing ibuprofen and codeine | |
| KR101136655B1 (en) | Pharmaceutical formulation comprising levothyroxine sodium | |
| JPH09500910A (en) | Film-coated tablets of paracetamol and domperidone | |
| JP5572321B2 (en) | Orally disintegrating tablets containing coated fine particles | |
| JP4113267B2 (en) | Loxoprofen sodium-containing tablets | |
| JP2000016930A (en) | Oral rapid disintegration tablet and its production | |
| JP4224866B2 (en) | Base with controlled dissolution time | |
| JP7385367B2 (en) | Orally disintegrating tablet | |
| EP1207857B1 (en) | Ciprofloxacin containing pharmaceutical composition and process for the preparation thereof | |
| MX2007016238A (en) | Prolonged release formulation of active principles having a ph-dependent solubility. | |
| UA79567C2 (en) | Orodispersible pharmaceutical composition of antithrombolic compound | |
| HU222109B1 (en) | Tablets containing captopril and process for producing them | |
| JP4824224B2 (en) | Sugar-coating preparations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A300 | Withdrawal of application because of no request for examination |
Free format text: JAPANESE INTERMEDIATE CODE: A300 Effective date: 20040106 |